Temple OrthoBio
Temple OrthoBio develops orthobiologics including TX-33, a drug designed to prevent scar tissue formation and accelerate recovery from injuries.
Temple OrthoBio develops next-generation orthobiologics to accelerate recovery and return to play. The company's lead product, TX-33, is described as the first drug that prevents scar formation. The team includes world-class surgeons, scientists, and athletes, with co-founder Riley J Williams III noted as a leading sports medicine orthopedic surgeon.